KR20110028457A - 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법 - Google Patents

신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법 Download PDF

Info

Publication number
KR20110028457A
KR20110028457A KR1020107028636A KR20107028636A KR20110028457A KR 20110028457 A KR20110028457 A KR 20110028457A KR 1020107028636 A KR1020107028636 A KR 1020107028636A KR 20107028636 A KR20107028636 A KR 20107028636A KR 20110028457 A KR20110028457 A KR 20110028457A
Authority
KR
South Korea
Prior art keywords
leptin
glu
val
ala
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107028636A
Other languages
English (en)
Korean (ko)
Inventor
니콜라오스 테자프시디스
스티븐 그레코
마크 스미스
Original Assignee
뉴로테즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 뉴로테즈 인코포레이티드 filed Critical 뉴로테즈 인코포레이티드
Publication of KR20110028457A publication Critical patent/KR20110028457A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107028636A 2008-05-21 2009-05-21 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법 Ceased KR20110028457A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5500908P 2008-05-21 2008-05-21
US61/055,009 2008-05-21

Publications (1)

Publication Number Publication Date
KR20110028457A true KR20110028457A (ko) 2011-03-18

Family

ID=41340901

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107028636A Ceased KR20110028457A (ko) 2008-05-21 2009-05-21 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법

Country Status (9)

Country Link
US (2) US8642543B2 (https=)
EP (1) EP2326339A4 (https=)
JP (1) JP5622720B2 (https=)
KR (1) KR20110028457A (https=)
CN (1) CN102099048A (https=)
AU (1) AU2009248914A1 (https=)
CA (1) CA2725143A1 (https=)
WO (1) WO2009143380A2 (https=)
ZA (1) ZA201008303B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
US8716220B2 (en) * 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
EP2393488B1 (en) * 2009-02-06 2019-06-19 University Of Southern California Therapeutic compositions comprising monoterpenes
US8507734B2 (en) 2010-03-03 2013-08-13 Neonc Technologies Inc. Pharmaceutical compositions comprising monoterpenes
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
EP3173080B1 (en) 2010-08-27 2019-12-11 Neonc Technologies Inc. Pharmaceutical compositions comprising derivatives of perillyl alcohol
CN105616391B (zh) 2010-12-17 2021-03-19 尼昂克技术公司 使用异紫苏醇的方法和装置
US20140088000A1 (en) * 2012-09-27 2014-03-27 Neurotez, Inc. Leptin Rescues Neurons from Alzheimer's Disease Related Pathways Triggered by Lipid Burden
WO2014165043A1 (en) * 2013-03-13 2014-10-09 Neurotez, Inc. Fragments, mutants and chimeric fusion proteins of leptin for treating alzheimer's disease
KR20170131405A (ko) 2015-02-12 2017-11-29 네온씨 테크놀로지스, 아이엔씨. 페릴릴 알코올 유도체를 포함하는 의약 조성물
DK3547836T3 (da) 2016-11-30 2024-11-18 Univ Southern California Perillylalkohol-3 brompyruvat-konjugat og fremgangsmåder til behandling af cancer
DK3749291T3 (da) 2018-02-08 2024-04-08 Univ Southern California Fremgangsmåder til permeabilisering af blod-hjerne-barrieren
BR112021018086A2 (pt) 2019-03-14 2021-11-23 Univ Arizona Método de tratamento e/ou prevenção de asma, exacerbações de asma, asma alérgica e/ou condições associadas com microbiota relacionadas a distúrbios respiratórios
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
CN114958760B (zh) * 2021-02-23 2024-04-26 南京启真基因工程有限公司 一种构建阿尔兹海默症模型猪的基因编辑技术及其应用

Family Cites Families (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
GB2129691B (en) 1982-10-08 1987-08-05 Glaxo Group Ltd Devices for administering medicaments to patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5837672A (en) 1992-07-10 1998-11-17 Athena Neurosciences, Inc. Methods and compositions for the detection of soluble β-amyloid peptide
US20020107211A1 (en) 1995-06-07 2002-08-08 The Rockefeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6048837A (en) 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
FI973162L (fi) 1995-01-31 1997-09-30 Lilly Co Eli Liikalihavuutta vastustavia proteiineja
US5559208A (en) 1995-01-31 1996-09-24 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5605886A (en) 1995-01-31 1997-02-25 Eli Lilly And Company Anti-obesity proteins
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5554727A (en) 1995-01-31 1996-09-10 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
CA2211656A1 (en) 1995-01-31 1996-08-08 Margret B. Basinski Anti-obesity proteins
AU5524896A (en) 1995-03-20 1996-10-08 Institut Pasteur De Lille Modulators of ob gene and screening methods therefor
ES2093593T1 (es) 1995-05-05 1997-01-01 Hoffmann La Roche Proteinas obesas (ob) recombinantes.
HUP9802609A2 (hu) 1995-06-30 1999-03-29 Eli Lilly And Co. A diabetes kezelésére szolgáló eljárás
US5698389A (en) 1995-11-16 1997-12-16 Tularik, Inc. Transcriptional promoter of the murine obesity gene
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
IL124831A0 (en) 1995-12-27 1999-01-26 Genentech Inc Ob protein derivatives having prolonged half-life
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US6025324A (en) 1996-05-15 2000-02-15 Hoffmann-La Roche Inc. Pegylated obese (ob) protein compositions
US5830450A (en) 1996-06-19 1998-11-03 Lallone; Roger L. Compositions of leptin bound to an apolipoprotein
US6630346B1 (en) 1996-06-20 2003-10-07 Merck & Co., Inc. Gene therapy for obesity
EP0954579A1 (en) 1996-06-20 1999-11-10 Merck & Co., Inc. Gene therapy for obesity
EP0921820A4 (en) 1996-06-20 2003-01-15 Merck & Co Inc GENETERAPY FOR OBESITY
US20060205660A1 (en) 1996-06-20 2006-09-14 Sauvage Frederic D OB protein-immunoglobulin chimeras
US6001816A (en) 1996-06-20 1999-12-14 Merck & Co., Inc. Gene therapy for leptin deficiency
WO1998024896A2 (en) 1996-12-06 1998-06-11 F. Hoffmann-La Roche Ag Muteins of obese protein
US20020019352A1 (en) 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
US6020004A (en) 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
ATE223229T1 (de) 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
IL120733A0 (en) 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
EP0950417A3 (en) 1998-02-23 2000-02-23 Pfizer Products Inc. Treatment of skeletal disorders
JP4215857B2 (ja) 1998-03-26 2009-01-28 裕 大村 学習・記憶能力改善剤
GB9807062D0 (en) 1998-04-02 1998-06-03 Imp College Innovations Ltd Immune response
EP1101112B1 (en) 1998-07-28 2004-10-06 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Leptin-mediated gene-induction
JP4199421B2 (ja) 1998-08-10 2008-12-17 アムジエン・インコーポレーテツド デキストラン−レプチン結合体、医薬組成物および関連方法
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
AU6396999A (en) 1998-10-02 2000-04-26 Amgen, Inc. Method to determine a predisposition to leptin treatment
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
EP1137340A4 (en) 1998-12-09 2005-12-21 Eleanor Roosevelt Inst COMPOSITION AND METHODS FOR REGULATION OF BODY WEIGHT AND ASSOCIATED PATHOLOGIES
HUP0105090A2 (hu) 1999-01-07 2002-04-29 Lexigen Pharmaceuticals Corporation Kóros elhízás elleni fehérjék expressziója és exportja Fc fúziós fehérje formájában
AU781460B2 (en) 1999-02-12 2005-05-26 Amgen, Inc. Glycosylated leptin compositions and related methods
US20030215423A1 (en) 1999-04-01 2003-11-20 Merck & Co., Inc. Gene therapy for obesity
US6475984B2 (en) 1999-04-29 2002-11-05 The Nemours Foundation Administration of leptin
CA2376933A1 (en) 1999-06-11 2000-12-21 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
AU767068B2 (en) 1999-06-11 2003-10-30 Baylor College Of Medicine Methods and compositions for control of bone formation via modulation of leptin activity
EP1210100B1 (en) * 1999-08-10 2006-06-14 UAB Research Foundation Method of treating traumatic brain using non-steroidal anti-inflammatory drugs
CA2382666A1 (en) 1999-08-23 2001-03-01 The Administrators Of The Tulane Educational Fund Modulation of the blood-brain barrier transporter for leptin
ATE342509T1 (de) * 2000-01-24 2006-11-15 Innogenetics Nv Diagnose von tauopathien durch bestimmung des verhältnisses von tau/phospho-tau
US7582292B2 (en) 2000-02-26 2009-09-01 Artecel, Inc. Adipose tissue derived stromal cells for the treatment of neurological disorders
US20030049255A1 (en) * 2001-08-07 2003-03-13 Sims John E. Interleukin-1 receptors in the treatment of diseases
US20050065078A1 (en) 2001-08-29 2005-03-24 Cawthorne Anthony Michael Use of leptin for infant with low birth weight for prevention of obesity
AU2002359288B2 (en) 2001-10-22 2008-07-31 Amgen, Inc. Use of leptin for treating human lipoatrophy and method of determining predisposition to said treatment
CN1630514A (zh) 2001-12-05 2005-06-22 贝勒医学院 通过调节交感神经紧张性控制骨形成的方法和组合物
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US7642281B2 (en) 2002-08-07 2010-01-05 Helicon Therapeutics, Inc. Indolone compounds useful to treat cognitive impairment
GB0323039D0 (en) * 2003-10-01 2003-11-05 Danisco Method
DE10353593A1 (de) 2003-11-17 2005-06-23 Klinikum der Universität München Großhadern-Innenstadt Leptinantagonist und Verfahren zur quantitativen Messung von Leptin
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
WO2005110468A2 (en) 2004-05-10 2005-11-24 The Burnham Institute Treatment of insulin resistance/metabolic syndrome to alleviate the risks of dementia
US20060281699A1 (en) 2004-05-12 2006-12-14 Merchiers Pascal G Methods, compositions and compound assays for inhibiting amyloid-beta protein production
US8043619B2 (en) 2004-10-08 2011-10-25 Yaron Ilan Methods and uses of leptin in immune modulation
US7863240B2 (en) 2004-10-08 2011-01-04 Enzo Therapeutics, Inc. Methods and uses of leptin in hepatocellular carcinoma
US7307142B2 (en) 2004-11-26 2007-12-11 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Leptin antagonists
US7629315B2 (en) 2005-03-09 2009-12-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compositions for blocking the inhibitory effect of human CRP on human leptin
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
US8716220B2 (en) 2005-09-07 2014-05-06 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
US9333240B2 (en) 2005-09-16 2016-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Compounds for improving nutritional status, cognition and survival
EP1795895A1 (en) 2005-12-08 2007-06-13 KeyNeurotek AG A tissue-based assay system for Alzheimer-specific degeneration and pathology
US20070218504A1 (en) 2006-03-09 2007-09-20 University Of Pittsburgh Human leptin-derived polypeptides and uses thereof
EP2032987B1 (en) 2006-05-22 2016-02-24 The Board of Trustees of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
WO2008048691A2 (en) 2006-10-18 2008-04-24 Amylin Pharmaceuticals, Inc. Use of leptin for treating post-lipectomy ectopic fat deposition and other post-lipectomy associated disorders
WO2008115880A2 (en) 2007-03-21 2008-09-25 The Board Of Regents Of The University Of Texas System Use of leptin for the treatment or prevention of parkinson's disease
US20100267630A1 (en) 2007-06-20 2010-10-21 Universitat De Les Illes Balears Use of leptin in the prevention of unhealthy food habits and cardiovascular diseases
US8889622B2 (en) 2007-07-25 2014-11-18 Washington University Methods of inhibiting seizure in a subject
US20090031434A1 (en) 2007-07-26 2009-01-29 Weiping Han Animal models for obesity and neurodegenerative diseases
WO2009108340A2 (en) 2008-02-27 2009-09-03 Temple University - Of The Commonwealth System Of Higher Education Leptin agonist and methods of use
US20110190215A1 (en) 2008-05-15 2011-08-04 Regen Therapeutics Plc Therapeutic use of peptides
CA2725143A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles

Also Published As

Publication number Publication date
JP5622720B2 (ja) 2014-11-12
AU2009248914A1 (en) 2009-11-26
US20140121157A1 (en) 2014-05-01
CN102099048A (zh) 2011-06-15
US20090291894A1 (en) 2009-11-26
WO2009143380A2 (en) 2009-11-26
ZA201008303B (en) 2012-04-25
US8642543B2 (en) 2014-02-04
JP2011520981A (ja) 2011-07-21
US20120010132A9 (en) 2012-01-12
EP2326339A4 (en) 2012-06-20
WO2009143380A3 (en) 2010-01-14
CA2725143A1 (en) 2009-11-26
EP2326339A2 (en) 2011-06-01

Similar Documents

Publication Publication Date Title
KR20110028457A (ko) 신경섬유 매듭과 연관된 신경변성 장애를 치료하는 방법
US8716220B2 (en) Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amyloid beta
KR102231074B1 (ko) 인슐린 글라진／릭시세나티드 고정비 제형
JP2021512051A (ja) ペプチドｙｙ薬学的調剤物、組成物、および方法
US20240000896A1 (en) Elevated intracranial pressure treatment
EP3197482A1 (en) Methods of treating traumatic brain injury
WO2008040260A1 (es) Uso del factor de crecimiento epidérmico para la restauración morfofuncional de nervios periféricos en la neuropatía diabética
JP2021130704A (ja) Ａｔ２ｒ活性を調節するための組成物および方法
CN110038114B (zh) 一种多肽在制备预防或治疗代谢综合征药物中的用途
CN101766811B (zh) 艾塞那肽或其类似物在制备治疗或预防糖尿病合并脑梗塞药物中的用途
HK40076546B (en) Incretin for elevated intracranial pressure treatment
HK40076546A (en) Incretin for elevated intracranial pressure treatment
TW202535919A (zh) 類升糖素肽2(glp-2)類似物之調配物及其用途
WO2025160184A1 (en) Methods for the prophylaxis and treatment of obesity and related conditions and disorders
TW202606654A (zh) 用於預防及治療肥胖及相關病狀及病症之方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20101220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20140521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20150909

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20160501

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20150909

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20160601

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20160501

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2016101003297

Request date: 20160601

J501 Disposition of invalidation of trial
PJ0501 Disposition of invalidation of trial

Comment text: Request for Amendment

Patent event date: 20151117

Patent event code: PJ05011S01I

Appeal kind category: Appeal against decision to decline refusal

Request date: 20160601

Appeal identifier: 2016101003297